AUTL Key Statistics, Chart & Performance
The current stock price of AUTL is 1.42 USD. In the past month the price decreased by -25.65%. In the past year, price decreased by -30.05%.
AUTL Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to AUTL. When comparing the yearly performance of all stocks, AUTL is a bad performer in the overall market: 79.79% of all stocks are doing better.
AUTL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AUTL. The financial health of AUTL is average, but there are quite some concerns on its profitability.
AUTL Financial Highlights
Over the last trailing twelve months AUTL reported a non-GAAP Earnings per Share(EPS) of -0.84. The EPS increased by 31.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -33.96% | ||
| ROE | -84.69% | ||
| Debt/Equity | 0.95 |
AUTL Forecast & Estimates
17 analysts have analysed AUTL and the average price target is 9.15 USD. This implies a price increase of 544.32% is expected in the next year compared to the current price of 1.42.
For the next year, analysts expect an EPS growth of -15.55% and a revenue growth 505.35% for AUTL
AUTL Ownership
AUTL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.39 | 387.092B | ||
| AMGN | AMGEN INC | 17.06 | 198.053B | ||
| GILD | GILEAD SCIENCES INC | 17.07 | 185.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.48 | 116.409B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.91 | 80.573B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.82 | 43.76B | ||
| INSM | INSMED INC | N/A | 32.21B | ||
| NTRA | NATERA INC | N/A | 27.199B | ||
| BIIB | BIOGEN INC | 13.02 | 27.192B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.47 | 20.623B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AUTL
Company Profile
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The firm has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. The company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Company Info
AUTOLUS THERAPEUTICS PLC
The Mediaworks, 191 Wood Lane
London W12 7RZ GB
CEO: Christian Itin
Employees: 647
Phone: 442038296230
AUTOLUS THERAPEUTICS PLC / AUTL FAQ
What does AUTL do?
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The firm has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. The company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
What is the stock price of AUTOLUS THERAPEUTICS PLC today?
The current stock price of AUTL is 1.42 USD. The price increased by 7.58% in the last trading session.
Does AUTOLUS THERAPEUTICS PLC pay dividends?
AUTL does not pay a dividend.
What is the ChartMill rating of AUTOLUS THERAPEUTICS PLC stock?
AUTL has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the growth outlook for AUTOLUS THERAPEUTICS PLC?
The Revenue of AUTOLUS THERAPEUTICS PLC (AUTL) is expected to grow by 505.35% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of AUTL stock?
AUTOLUS THERAPEUTICS PLC (AUTL) has a market capitalization of 377.92M USD. This makes AUTL a Small Cap stock.
Can you provide the upcoming earnings date for AUTOLUS THERAPEUTICS PLC?
AUTOLUS THERAPEUTICS PLC (AUTL) will report earnings on 2026-03-18, after the market close.